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Abstract Background
Infection acquired in hospital is an important cause of morbidity and mortality in very preterm infants. Several small trials have suggested that supplementing the enteral diet of very preterm infants with lactoferrin, an antimicrobial protein usually processed from cow's milk, prevents infections and associated complications.
Methods
In this randomised, placebo-controlled trial, very preterm infants (born before 32 weeks' gestation) were recruited within 72 hours of birth from 37 UK hospitals. Infants were allocated randomly (1:1) to receive enteral bovine lactoferrin (150 mg/kg/day; maximum 300 mg/day) versus sucrose (same dose) once daily until 34 weeks' postmenstrual age. Web-based randomisation used an algorithm minimised for recruitment site, gestation (completed weeks), sex, and single versus multifetal pregnancy. Parents, caregivers and outcomes assessors were unaware of group assignment. The primary outcome was microbiologically-confirmed or clinically-suspected late-onset infection until hospital discharge. The trial was registered with the International Standard Randomised Controlled Trial Number 88261002.
Findings
We recruited 2203 participants between May 2014 and September 2017. Four infants had consent withdrawn or unconfirmed leaving 1098 infants in the lactoferrin group and 1101 in the sucrose group. Primary outcome data for 2182 infants were available for inclusion in the intention-to-treat analyses. In the intervention group, 316/1093 (28.9%) infants acquired a late-onset infection versus 334/1089 (30.7%) in the control group: risk ratio (RR) adjusted for minimisation factors 0.95 (95% confidence interval [CI] 0.81, 1.10). Pre-specified subgroup analyses did not show statistically significant interactions for gestation at birth (completed weeks') or type of enteral milk received (human, formula, or both).
Introduction
Late-onset infection (occurring >72 hours after birth) is the most common serious complication associated with hospital care for preterm infants. The James Lind Alliance Preterm Birth Priority Setting Partnership has identified the development and assessment of better methods to prevent infection in preterm infants as a research priority. 1 The incidence of late-onset infection is typically estimated to be higher than 20% in very preterm infants (born before 32 weeks' gestation) reflecting their duration of exposure to invasive procedures and intensive care. 2 Very preterm infants who acquire a late-onset infection have a higher risk of mortality and a range of acute morbidities including necrotising enterocolitis (NEC), retinopathy of prematurity (ROP), and bronchopulmonary dysplasia (BPD). 3 Late-onset infection is associated with adverse neurodevelopmental outcomes including visual, hearing, and cognitive impairment, and cerebral palsy. 4 As a consequence of associated morbidities, very preterm infants with late-onset infection spend a longer time in hospital than gestation-comparable infants without infection. 5 Late-onset infection therefore has major consequences for perinatal health care service management, delivery, and costs.
Lactoferrin, a member of the transferrin family of iron-binding glycoproteins, is a key component of the mammalian innate response to infection. It is the major whey protein in human breast milk, present at a concentration of about 1 mg/mL. Lactoferrin has broad microbiocidal activity by mechanisms such as cell membrane disruption, iron sequestration, inhibition of microbial adhesion to host cells, and prevention of biofilm formation. 6 It promotes the growth of probiotic bacteria, stimulates differentiation and proliferation of enterocytes and expression of intestinal digestive enzymes, and has direct intestinal immunomodulatory and anti-inflammatory actions including suppression of free radical activity. 7, 8 Very preterm infants typically ingest little or no milk during the early neonatal period and have low intake of lactoferrin. 9 This is exacerbated by any delays in establishing enteral feeding.
Enteral supplementation with bovine lactoferrin has been proposed as a simple strategy to compensate for this immuno-deficiency. 10 Bovine lactoferrin is about 70% homologous with human lactoferrin but has higher antimicrobial activity. 11 It is inexpensive compared with human or recombinant lactoferrin, is available commercially as a food supplement in a stable powder form, and is registered as 'Generally Recognised As Safe' by the US Federal Drug Administration with no reports of human toxicity. 12 The 'no-observed-adverse effect level' is more than 2g/kg/day in rodents. 13 The European Food Safety Authority Panel has concluded that bovine lactoferrin for infants is safe at the standard supplementation levels (up to about 210 mg/kg of body weight per day). 14 The current Cochrane review of enteral lactoferrin supplementation for preterm infants includes six randomised controlled trials (RCTs) involving 1071 participants in total. 15 Metaanalyses suggest that lactoferrin supplementation reduces the risk of late-onset infection by about 40%. The risk of NEC is decreased by about 60%. No adverse effects or intolerance were reported. Because the included trials were small and contained methodological weaknesses associated with selection and performance bias, and because meta-analyses were limited by data availability and heterogeneity, the Grading of Recommendations Assessment, Development and Evaluation working group assessment of the quality of this evidence was low. The Cochrane reviewers concluded that data from large, good-quality RCTs of lactoferrin supplementation in very preterm infants were needed to enhance the validity and applicability of the evidence to inform practice. 15 The aim of the ELFIN trial was to provide those data. 16 
Methods

Study design
This randomised, parallel-group, placebo-controlled trial was conducted in neonatal units in the UK (37 recruiting sites and 97 continuing care sites; see appendices 1 and 3). The trial protocol was approved by the National Research Ethics Service (NRES) Committee East Midlands -Nottingham 2 (Ref: 13/EM/0118). Local approval and site-specific assessments were obtained from the NHS Trusts for trial sites.
The protocol is available at the trial website (https://www.npeu.ox.ac.uk/elfin) and is published in summary form. 17 Protocol changes are listed in appendix 3.
Participants
Eligible participants were very preterm infants (gestational age at birth <32 weeks) who were <72 hours old at randomisation. Exclusion criteria were presence of a severe congenital anomaly, anticipated enteral fasting for longer than 14 days, or no realistic prospect of survival. Written consent was sought from the parents only after they had received a full verbal and written explanation of the trial. Parents who did not speak English were approached only if an adult interpreter was available. Neither trial participants nor their parents were given any material incentive or compensation to take part. Parents remained free to withdraw their infant from the trial at any time without the need to provide a reason or explanation. Parents were aware that this decision would have no impact on any aspects of their infant's care.
Randomisation
Allocation of participants to study groups was managed via a secure web-based randomisation facility at the National Perinatal Epidemiology Unit (NPEU), University of Oxford (https://rct.npeu.ox.ac.uk/). A Senior Trials Programmer at the NPEU wrote the randomisation program and held the code. Telephone assistance and randomisation back-up was available at all times.
To confirm participant eligibility, investigators supplied gestational age, sex, and time of birth.
To proceed to randomisation, investigators confirmed that signed informed consent was available. Infants were allocated to a trial group in a 1:1 ratio using a minimisation algorithm to ensure balance between the groups in recruiting site (neonatal unit), sex, single versus multiple births, and gestational age in completed weeks. Twins or higher order multiple birth infants were randomised individually. Infants were considered to have been enrolled once they had been given a unique study number and allocated a treatment pack identification (ID) number. Parents, clinicians, investigators, and outcomes assessors were unaware of the allocated treatment groups.
Intervention
Trial participants were allocated to receive either: number to indicate that they all belonged to the same treatment course. At randomisation, the study number was added to the label of the allocated pack with the infant's name and date of birth for checking before each administration of the IMP.
Prescription and preparation
The IMP was prescribed at a dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day). The IMP was prepared for administration by addition by syringe of sterile water (4 mL) plus expressed breast milk or formula (1 mL). The pot was shaken vigorously by hand for 30 seconds to generate a mixture containing 75mg/mL of IMP. The mixture was allowed to stand for 30 minutes before removal for administration using an enteral feeding syringe.
The IMP was administered once daily by naso-or oro-gastric tube once the infant's enteral feed volume was >12 mL/kg/day and continued until 34 weeks' postmenstrual age. Small infants may have had the dose split at the discretion of the responsible clinical team. All other aspects of care including the timing of the commencement of enteral feeds and the type of milk feed used were as per local policy, practice, and discretion. Administration of the trial IMP may have been stopped temporarily. Missed doses did not necessitate the removal of an infant from the trial. Data continued to be collected as per protocol if the trial medication was stopped. When the infant completed the course of treatment, any unused IMP pots were accounted for and destroyed.
Masking
Bovine lactoferrin has a pale pink-brown tinge, whereas sucrose was very light brown. The opaque containers did not allow the dry IMP to be seen unless the sealed stopper was removed intentionally. The lactoferrin powder had similar granularity to sucrose so that when the dry IMP was shaken within the opaque, sealed pots it was not possible to distinguish lactoferrin from sucrose by the sound generated. Mixing the IMP with sterile water plus breast milk or formula generated foam that settled within 30 minutes after shaking. When the mixed IMP was removed in a syringe with a purple plunger, the pink tinge to the lactoferrin was disguised by the colour of the breast milk or formula which often resulted in a light brown colour (and this varied markedly between batches of milk). As lactoferrin was more likely than sucrose to retain a light pink tinge, we supplied all sites with a laminated picture of a range of possible colours for the IMP mixture in syringes, and stressed that this applied to both lactoferrin and sucrose.
Clinicians were able to request knowledge of the treatment allocation to guide the clinical management of the participant if it was deemed to be an emergency situation. In such instances, a single-use access code was provided in a sealed envelope and the participants allocation was unmasked via the randomisation website.
Outcomes
Primary outcome
The primary outcome was microbiologically-confirmed (box 1) or clinically-suspected (box 2) late onset-infection from trial entry until hospital discharge.
Secondary Outcomes
• Microbiologically-confirmed infection
• All-cause mortality prior to hospital discharge
• NEC (Bell's stage II or III) 19 • Severe ROP treated medically or surgically 20 • BPD: where the infant is still receiving mechanical ventilator support or supplemental oxygen at 36 weeks' postmenstrual age 21
• A composite of invasive infection, major morbidity (NEC, ROP, or BPD), and mortality • increase in oxygen requirement or ventilatory support
• increase in frequency of episodes of bradycardia or apnoea
• temperature instability
• ileus or enteral feeds intolerance or abdominal distention
• reduced urine output to <1 ml/kg/hour
• impaired peripheral perfusion (capillary refill time >3 seconds, skin mottling or coreperipheral temperature gap >2°C)
• hypotension (clinician defined as needing volume or inotrope support)
• 'irritability or lethargy or hypotonia' (clinician-defined)
• increase in serum C-reactive protein levels to > 15 mg/L or procalcitonin ≥ 2 ng/mL
• white blood cells count < 4 or > 20 × 10 9 /L
• cells/l or platelet count < 100 × 10 9 /L
• glucose intolerance (blood glucose < 40 mg/dL or > 180 mg/dL)
• metabolic acidosis (base excess (BE) < -10 mmol/L or lactate > 2 mmol/L)
Adverse Events
Some adverse events were expected due to the nature of the participant population and their routine care and treatment. No adverse drug reactions were expected from bovine lactoferrin. The CI submitted annually or on request a Development Safety Update Report (DSUR) to the Competent Authority, the approving Research Ethics Committee, and the sponsor.
Sample size
The sample size estimate was informed by a range of plausible primary outcome control event rates (CER) from 18% to 24%. 2, 3 In summary, with 90% power and a two-sided 5% significance level, to detect an absolute risk reduction (ARR) of 5-5.8% (relative risk reduction of between 24% and 28%) would require a total of up to 2,200 participants if the control group event rate (CER) was 18%, 2,070 if the CER was 21%, and 2,076 if the CER was 24%. This target sample size of 2,200 allowed for an anticipated loss to follow-up of up to 5%.
Statistical analysis
The analyses were conducted using STATA/SE version 13.1 for Windows. 22 Characteristics at randomisation were summarised with counts (percentages) for categorical variables, mean (standard deviation [SD] ) for normally distributed continuous variables, or median (interquartile [IQR] or entire range) for other continuous variables.
Outcomes for participants were analysed in the groups to which they were assigned.
Comparative analyses calculated the relative risk ratio (RR) with 95% confidence interval (CI)
for the primary outcome (99% CIs for all other dichotomous outcomes), the mean difference (99% CI) for normally distributed continuous outcomes, or the median difference (99% CI) for skewed continuous variables.
The groups were compared using regression analysis adjusting for the minimisation factors to account for the correlation between treatment groups introduced by balancing the randomisation. The crude unadjusted and adjusted estimates were calculated with the primary inference to be based on the adjusted analysis.
The consistency of the effect of lactoferrin supplementation on the primary outcome across specific subgroups of infants was assessed using the statistical test of interaction. Pre-specified subgroups were (i) completed weeks' gestation at birth, and (ii) infants given human breast milk versus formula versus both human milk and formula during the trial period.
During the trial, the trial statisticians produced reports for the DMC. Issues of data quality identified by trial statisticians were reported to study data management staff and queried when appropriate or included in future routine data validation checks, or both. Trial Steering Committee (TSC) and DMC meetings provided opportunities for external, independent review of summary data, with additional feedback on potential data quality issues being incorporated into ongoing data quality checks. 
Trial registration
Results
Recruitment and retention to the trial are summarised in the flowchart (Figure 1 ). The trial recruited 2203 participants in 37 neonatal units between 7 th May 2014 and 28th September 2017. Four infants had consent withdrawn or unconfirmed. In total, 1098 infants in the lactoferrin group and 1101 in the placebo group were included in the intention-to-treat analyses. The baseline characteristics and other demographic features of participating infants in the two treatment allocation groups are presented in Table 1 .
A total of 35 (1.6%) infants discontinued the intervention early; 20 in the lactoferrin group and 15 in the sucrose group (appendix 4). Parental consent remained for data collection for intention-to-treat analyses for 32 of the 35 infants.
Adherence was high for infants who continued to receive the IMP. The median percentage of days when an IMP dose was not given or not recorded was 4% in both treatment groups. The median difference between expected dose and actual dose per day was 7 mg/kg/day lower in both groups, and was 1 mg/kg/day (lactoferrin) or 2 mg/kg/day (sucrose) lower excluding those days where enteral feeds were stopped or withheld for more than 4 hours. Unless otherwise stated the table gives the percentages of babies with data in that arm of the trial who had (or whose mother had) the stated characteristic.
The estimates of effect for the primary and secondary outcomes are presented in Table 2 .
Data were available for 2182 infants (99% (Figure 2 ).
Post hoc analyses did not show any effects depending upon the infecting microorganism identified for the outcome "microbiologically-confirmed late-onset infection" (Table 3 ).
Post hoc analysis did not show any difference in primary outcome by trial group depending upon whether infants had received probiotics as part of routine care or not (Table 4 ).
There were no significant differences in secondary outcomes: microbiologically-confirmed There were 16 SAEs reported for infants in the lactoferrin group (6 severe), and 10 for the sucrose group (3 severe). Two SAEs, both in the lactoferrin group, were assessed as being "possibly related" to the trial intervention; one case of blood in stool (expected), and one death following intestinal perforation likely associated with NEC (SUSAR). The remaining 24 SAEs were considered to be unrelated to the trial intervention. 
Discussion
These data suggest that enteral lactoferrin supplementation (150 mg/kg/day until 34 weeks postmenstrual age) does not reduce the risk of late-onset infection, other morbidity, or mortality in very preterm infants. This contradicts previous trial findings.
The current Cochrane review includes six RCTs and meta-analyses suggest substantial reductions in the risk of late-onset infection and NEC associated with lactoferrin supplementation in very preterm infants. 15 The included trials, however, were small and some contained other design and methodological weaknesses that may have introduced performance and detection biases resulting in over-estimation of the treatment effects. Given these concerns, the Cochrane review authors graded the evidence for key outcomes as "low quality" and concluded that data from large, methodologically-rigorous RCTs were needed to generate evidence of sufficient validity to inform policy and practice,
The ELFIN trial provides these data. We used practices to limit bias including central web based randomisation for allocation concealment, blinding of parents, caregivers and investigators to the group allocation, and complete follow up and assessment of the trial cohort with intention-to-treat analyses based on a pre-specified statistical analysis plan. The trial achieved recruitment of >2200 participants as per protocol based on the a priori sample size estimation. Demographic and prognostic characteristics were wellbalanced at randomisation. Interim analyses by the trial's independent DMC used strict criteria to minimise the chances of spurious findings due to data fluctuations before a sufficient sample size was achieved. 23, 24 Adherence to the allocated interventions was high, the incidence of protocol violations was low, and outcome data were available for >99% of the trial cohort. Event rates for the primary and secondary outcomes were broadly similar to those anticipated. 2, 3 Consequently, the trial had sufficient power and internal validity to detect reliably modest yet important effects on the risk of late-onset infection and other morbidity.
The ELFIN trial enrolled more than twice as many infants than had participated in all of the existing trials combined and generated more precise estimates of effect size than were available previously. The 95% CI for the relative risk estimate for the primary outcome excludes a >19% RR reduction and a >10% increase in risk. These estimates were consistent across gestational age bands making it unlikely that bovine lactoferrin has any important benefits for extremely preterm infants who have a higher risk of infection. Similarly, although plausible that lactoferrin may have had different effects in infants with lower levels of exposure to the immuno-protective factors present in human milk, we did not show any interaction with the type of enteral milk feeds received during the trial period (human milk, formula, or both).
The pre-specified primary outcome included "clinically-suspected" and "microbiologically-confirmed" late-onset infection. We took this pragmatic approach because of concerns about the diagnostic accuracy of microbiological culture of blood in this population. 25 Standard microbiological culture may not detect cases of bacteraemia or fungaemia if an insufficient volume of the infant's blood is incubated ("false negative"). Conversely, microbiological cultures may also generate "false positive"
results if blood sampling techniques allow entry of contaminating microorganisms (typically from the infant's skin). To mitigate these potential sources of bias, we used an established consensus case-definition that (i) required additional evidence of infection (clinical signs or biomarkers), and (ii) mandated that clinicians indicate an intention to treat the infant with antibiotics or antifungals for at least five days. 2 Given that a postulated mechanism of action of lactoferrin is to reduce bowel translocation of enteric pathogens, we assessed post hoc whether invasive infections with particular groups of enteric organisms were reduced. We did not find any evidence that lactoferrin supplementation affected the risk of late-onset infection with different groups of infecting microorganism including Gram-negative bacteria (mainly E. coli and other enterobacteriaceae).
In a post hoc subgroup analysis of infants who had or had not received routine probiotic supplementation during the trial period, we did not show any difference in the effect of lactoferrin on the risk of late-onset infection. A previous trial and the current Cochrane review had suggested that combining supplementation of lactoferrin with the probiotic microorganism Lactobacillus rhamnosus GG (LGG) was associated with a greater reduction in the risk of late-onset infection and NEC than lactoferrin alone. 15, 26 This raises the possibility that the immuno-protective and prebiotic properties of lactoferrin might act synergistically with probiotic supplementation. 27 Although the ELFIN trial did not show any evidence of differential effects depending upon whether infants had received probiotics during the trial period, the data are not sufficient to exclude the possibility that such prebiotic-probiotic synergism exists. A recent large cluster RCT in India has suggested that prophylactic administration of an oral synbiotic (prebiotic fructo-oligosaccharide combined with probiotic Lactobacillus plantarum ) reduces infection and mortality in late-preterm or term newborn infants. 28 We are conducting a mechanistic study in a subgroup of ELFIN trial participants to analyse whether and how lactoferrin supplementation affects the intestinal microbiome and metabolite profile.
The study will explore changes in microbiomic and metabolomic patterns preceding disease onset including NEC and late-onset infection. 27 Estimates for the secondary outcomes indicated consistently that lactoferrin supplementation does not have important effects on the risk of major morbidities: NEC, BPD, and ROP. We pre-specified an analysis of the effect on a composite of major morbidity and mortality since these outcomes may be competing. The adjusted risk ratio point estimate for this secondary outcome was 1.01, with a 99% CI excluding a >14% reduction and a >18% increase in risk. We plan to increase the precision of these estimates of effect on rarer secondary outcomes by combining these data in a metaanalysis with other trials including a recently-completed Australasia RCT (N= 1500) of bovine lactoferrin supplementation for very low birth weight infants (Lactoferrin Infant
Feeding Trial: www.anzctr.org.au/ACTRN12611000247976.aspx).
Since late-onset infection and NEC are the major reasons for receipt of invasive interventions and higher levels of "categories of care" in very preterm infants after the early neonatal period, it is not surprising that we did not show any effects on the level of exposure to antimicrobial agents, or on the duration of hospitalisation, or stay in intensive or high dependency care settings. Given that the ELFIN trial did not show any differences between groups in the risk of morbidity or on levels of care received, we did not undertake further analyses of healthcare costs as had been proposed in our approved funding application and trial protocol. We did not conduct a within-trial health economic analysis or use these data in a model to explore long term family and health service costs since these are driven mainly by the consequences of infection and other morbidity during the initial hospitalisation. Without evidence of clinical effectiveness on these infant-important outcomes, we considered a cost-effectiveness analysis of lactoferrin supplementation to be futile. 29 We do not plan to apply for permission and funding to assess longer term outcomes of trial participants. We specified in our protocol that if the trial did not detect statistically significant or clinically important differences in the in-hospital outcomes then follow-up will not be undertaken since any between group differences in growth and neurodevelopmental outcomes are predicated largely on differences in the incidence of late-onset infections, NEC and associated morbidities. 4 Since these were not shown there is no longer an impelling rationale for expecting lactoferrin supplementation to impact on long term growth or development.
The ELFIN trial findings are likely to be applicable in the UK and internationally. The trial population was representative of very preterm infants cared for within healthcare facilities in well-resourced health services and included a substantial proportion of extremely preterm infants and of infants with other putative risk factors for neonatal morbidity. Overall, about 30% of participants acquired a microbiologically-confirmed or clinically-suspected late-onset infection, and about 17% in total had a microbiologicallyconfirmed infection, consistent with rates reported from cohort studies and other RCTs.
Similarly, the incidence of NEC (about 5%) was similar to rates reported in large, population-based surveillance and cohort studies and RCTs. 30 In conclusion, the ELFIN trial does not support the routine use of enteral bovine lactoferrin supplementation to prevent late-onset infection or other morbidity or mortality in very preterm infants. Research efforts should continue to investigate the aetiology, epidemiology, and pathogenesis of late-onset infection and related morbidities, and to develop, refine, and assess other interventions that may prevent or reduce adverse acute and long term consequences for very preterm infants and their families.
Research in context
Evidence before this study
The 2011 
Added value of this study
The ELFIN trial shows that enteral supplementation of bovine lactoferrin (150 mg/kg/day until 34 week's postmenstrual age) does not reduce the risk of late-onset infection, other morbidity, or mortality in very preterm infants. This is the largest trial of this intervention and the validity is enhanced by the methodological quality and power. The findings are broadly applicable to very preterm infants cared for in facilities in well-resourced health services. There was no indication of any beneficial effects for infants with additional risk factors for late-onset infection, including extreme preterm birth.
Implications of all the available evidence
The ELFIN trial findings contradict the existing evidence-base and illustrates why highquality evidence from adequately powered RCTs is needed to inform policy and practice. The 2017 update of the Cochrane review includes six RCTs, but most were small and some contained other design and methodological weaknesses that may have introduced biases resulting in over-estimation of the effect sizes. With more than twice as many participants than had been enrolled in all of the previous trials combined, the ELFIN trial generated more precise estimates of effect, and provides valid and applicable evidence that enteral bovine lactoferrin supplementation does not reduce substantially the risk of late-onset infection or other morbidity or mortality in very preterm infants. Table 2 , maximum expiry will be 
